20:48 , Oct 5, 2018 |  BC Week In Review  |  Company News

Roche gains CD25 program via Tusk takeout

Roche (SIX:ROG; OTCQX:RHHBY) acquired cancer immunotherapy company Tusk Therapeutics Ltd. (Stevenage, U.K.) for €70 million ($82.2 million) up front. Tusk shareholders are eligible to receive €585 million ($686.8 million) in undisclosed milestones. Roche will gain...